Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†

被引：0
|
作者：
Jennifer S. Orman
Gillian M. Keating
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
CNS Drugs | 2009年 / 23卷
关键词：
Clonidine; Naloxone; Buprenorphine; Withdrawal Syndrome; Opioid Antagonist;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Buprenorphine/naloxone (Suboxone®) comprises the partial μ-opioid receptor agonist buprenorphine in combination with the opioid antagonist naloxone in a 4: 1 ratio. When buprenorphine/naloxone is taken sublingually as prescribed, the naloxone exerts no clinically significant effect, leaving the opioid agonist effects of buprenorphine to predominate. However, when buprenorphine/naloxone is parenterally administered in patients physically dependent on full agonist opioids, the opioid antagonism of naloxone causes withdrawal effects, thus reducing the abuse potential of the drug combination.
引用
收藏
页码：899 / 902
页数：3
相关论文
共 50 条
  • [1] Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence
    Orman, Jennifer S.
    Keating, Gillian M.
    CNS DRUGS, 2009, 23 (10) : 899 - 902
  • [2] Opioid dependence treatment, including buprenorphine/naloxone
    Raisch, DW
    Fye, CL
    Boardman, KD
    Sather, MR
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (02) : 312 - 321
  • [3] Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence
    Soyka, Michael
    EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (11) : 1409 - 1417
  • [4] Buprenorphine-Naloxone Treatment in Physicians and Nurses With Opioid Dependence
    Dolores Braquehais, Maria
    Fadeuilhe, Christian
    Hakansson, Anders
    Jordi Bel, Miquel
    Cecilia Navarro, Maria
    Roncero, Carlos
    Bruguera, Eugeni
    Casas, Miquel
    SUBSTANCE ABUSE, 2015, 36 (02) : 138 - 140
  • [5] Buprenorphine/Naloxone A Review of its Use in the Treatment of Opioid Dependence
    Orman, Jennifer S.
    Keating, Gillian M.
    DRUGS, 2009, 69 (05) : 577 - 607
  • [6] Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone
    Rosenthal, Richard N.
    Ling, Walter
    Casadonte, Paul
    Vocci, Frank
    Bailey, Genie L.
    Kampman, Kyle
    Patkar, Ashwin
    Chavoustie, Steven
    Blasey, Christine
    Sigmon, Stacey
    Beebe, Katherine L.
    ADDICTION, 2013, 108 (12) : 2141 - 2149
  • [7] Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence
    Heo, Young-A
    Scott, Lesley J.
    CNS DRUGS, 2018, 32 (09) : 875 - 882
  • [8] Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence
    Young-A Heo
    Lesley J. Scott
    CNS Drugs, 2018, 32 : 875 - 882
  • [9] IN BRIEF Buprenorphine/Naloxone (Zubsolv) for Opioid Dependence
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1427): : 83 - 83
  • [10] Bunavail: Another Buprenorphine/Naloxone Formulation for Opioid Dependence
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1461): : 19 - 20
12345